Pharmacological Interventions
While there are currently no medications that directly alleviate the core social-communication difficulties associated with ASD, there are medications that can help with some of the common co-existing conditions that individuals on the autism spectrum experience1. Some of these various medications are listed below (it is important to be aware that the medications can be sold under different brand names). The research findings on the use of medications for individuals with ASD are mixed, and this is particularly true in studies which examined pharmacological approaches to the management of depression and anxiety2. Individual responses to medication can differ based on age, co-occurring conditions, and the specific challenges each person faces.
Medications are prescribed by suitably qualified medical doctors. It should be kept in mind that prescribed medication can have certain side effects, particularly with long-term use, making regular monitoring by a physician essential. The choice of medication should always be tailored to the individual, balancing potential benefits with any risks.
Some key areas where medication may be considered for individuals with autism include:
- Aggression, Irritability, and Social Withdrawal: Aggression, irritability and/or social withdrawal can occur in some individuals with autism. Antipsychotic medications, such as risperidone and haloperidol, are sometimes prescribed to help alleviate these behaviours3. By reducing aggression and other severe behavioural challenges, these medications can contribute to an improved quality of life for both the individual and their family.
- Comorbid ‘Attention Deficit Hyperactivity Disorder’ (ADHD): Some individuals with ASD have co-existing ADHD, which can make it difficult for them to focus and engage in daily activities. Stimulant medications, such as methylphenidate (often sold under the brand names of Ritalin and Concerta), may be prescribed by a psychiatrist to help manage these symptoms4. This in turn can make it easier for individuals with ASD and comorbid ADHD to participate in interventions and engage in learning activities.
- Anxiety and Mood Disorders: Anxiety and depressive symptoms are experienced by many individuals with ASD, something that can intensify their difficulties with social interactions and adherence to daily routines. The GP or psychiatrist can advise on the use of medications to help alleviate anxiety and mood issues, and whether a given individual is a suitable candidate for such medication.
- Sleep Disturbances: Sleep problems are experienced by many individuals with ASD, something which can impact significantly on their quality of life. Melatonin, a natural hormone, is sometimes prescribed to improve sleep onset and sleep quality5.
References
- McDonald, M. E., & DiGennaro Reed, F. D. (2018). Distinguishing science and pseudoscience in the assessment and treatment of autism spectrum disorder. In S. Goldstein & S. Ozonoff (Eds.), Assessment of autism spectrum disorder (pp. 415–441). New York, NY: The Guilford Press.
- Deb, S., Roy, M., Lee, R., Majid, M., Limbu, B, Santambrogio, J., Roy, A., & Bertelli, M. O. (2021). Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: Systematic review and meta-analysis. BJPsych Open, 7(6):e179. doi: 10.1192/bjo.2021.1003
- Posey, D. J., Stigler, K. A., Erickson, C. A., & McDougle, C. J. (2008). Antipsychotics in the treatment of autism. Journal of Clinical Investigation, 118(1), 6-14. doi: 10.1172/JCI32483
- Ventura, P., de Giambattista, C., Spagnoletta, L., Trerotoli, P., Cavone, M., Di Gioia, A., & Margari, L. (2020). Methylphenidate in autism spectrum disorder: A long-term follow up naturalistic study. Journal of Clinical Medicine, 9(8):2566. doi: 10.3390/jcm9082566
- Nogueira, H. A., de Castro, C. T., da Silva, D. C. G., & Pereira, M. (2023). Melatonin for sleep disorders in people with autism: Systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 123: 110695. doi: 10.1016/j.pnpbp.2022.110695



